期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

程序性死亡配体-1及其抑制剂在非小细胞肺癌中的研究进展 被引量：1

Advances of programmed death ligand 1 and its inhibitor in non-small cell lung cancer
原文传递
导出
摘要 程序性死亡配体-1（PD-L1）以细胞膜型PD-L1和可溶性PD-L1两种形式在NSCLC中高表达，通过与其受体结合参与肿瘤免疫逃逸。目前PD-L1抑制剂已进入NSCLC的Ⅰ期临床试验并反应良好，其治疗敏感性与肿瘤组织PD-L1的表达状态显著相关，因而PD-L1有望成为预测其药物疗效的生物学标志物。 Programmed deathligand 1 （PD-L1）, which is highly expressed in NSCLC, can be divided into two categories： membrane PD-L1 and soluble PD-L1. PD-L1 participates in tumor immune escape through combining with its receptor. PD-L1 immune checkpoint inhibitors have entered the phase Ⅰ studies and showed a good application prospect. It is also found that the sensitivity of PD-L1 immune checkpoint inhibitors is strongly associated with the expression of PD-L1 in tumor. Therefore, PD-L1 can be used as a biomarker to predict its curative effect.
作者 耿睿 潘莉 宋霞
机构地区 山西医科大学附属肿瘤医院呼吸二病区
出处 《国际肿瘤学杂志》 CAS 2015年第8期628-630,共3页 Journal of International Oncology
关键词 癌 非小细胞肺 免疫抑制剂 程序性死亡配体-1 Carcinoma, non-small cell lung Immunosuppressive agents Programmed death ligand 1
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献18

  • 1Errico A. Immunotherapy: PD-I-PD-Ll axis: efficient checkpoint blockade against cancer[J] . Nat Rev Clin Oncol, 2015, 12 ( 2 ) : 63.
  • 2Chen YB, Mu CY, HuangJA. Clinical significance of programmed death-I ligand-I expression in patients with non-small cell ?lung cancer: a 5-year-follow-up study[J]. Tumori, 2012, 98(6): 751- 755.
  • 3Kim MY, KohJ, Kim 5, et al. Clinicopathological analysis of PD-Ll and PD-12 expression in pulmonary squamous cell carcinoma: com?parison with tumor-infiltrating T cells and the status of oncogenic drivers[J]. Lung Cancer, 2015, 88(1): 24-33.
  • 4马薇,罗殿中,陈源,党裔武.PD-L1和PD-1在非小细胞肺癌中的表达及其临床意义[J].实用医学杂志,2011,27(9):1551-1554. 被引量：57
  • 5Chen Y, Wang Q, Shi B, et al. Development of a sandwich ELISA for evaluating soluble PD-Ll (CD274) in human sera of different ages as well as supernatants of PD- Ll + cell lines[J]. Cytokine, 2011,56(2): 231-238.
  • 6Akbay EA, Koyama 5, CarreteroJ, et al. Activation of the PD-l pathway contributes to immune escape in EGFR-driven lung tumors[J]. Cancer Discov, 2013, 3 (12) : 1355-1363.
  • 7Azuma K, Ota K, Kawahara A, et al. Association of PD-Ll overex?pression with activating EGFR mutations in surgically resected non?small cell lung cancerj L], Ann Oncol, 2014, 25(10): 1935-1940.
  • 8D' Incecco A, Andreozzi M, Ludovini V, et al. PD-l and PD- Ll expression in molecularly selected non-small-cell lung cancer patients[J]. BrJ Cancer, 2015,112(1): 95-102.
  • 9Maekawa N, Konnai 5, Ikebuchi R, et al. Expression of PD- Ll on canine tumor cells and enhancement of IFN -'Y production from tumor?infiltrating cells by PD-Ll blockade[J]. PLoS One, 2014, 9 (6) : e98415.
  • 10Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition[J]. Nat Rev Immunol, 2013,13(4): 227-242.

二级参考文献8

  • 1Carter L,Fouser L A,Jussif J,et al.PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2[J].Eur J Immunol,2002,32(3):634-643.
  • 2Latchman Y,Wood C R,Chernova T,et al.PD-L2 is a second ligand for PD-1 and inhibits T cell activation[J].Nat Immunol,2001,2(3):261-268.
  • 3Dong H,Zhu G,Tamada K,et al.B7-H1,a third member of the B7 family,co-stimulates T-cell proliferation and interleukin-10 secretion[J].Nat Med,1999,5(12):1365-1369.
  • 4Al-Shibli K,Al-Saad S,Donnem T,et al.The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma[J].Histopathology,2009,55(3):301-312.
  • 5Haspot F,Fehr T,Gibbons C,et al.Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway[J].Blood,2008,112(5):2149-2155.
  • 6Konishi J,Yamazaki K,Azuma M,et al.B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression[J].Clin Cancer Res,2004,10(15):5094-5100.
  • 7Wu K,Kryczek I,Chen L,et al.Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions[J].Cancer Res,2009,69(20):8067-8075.
  • 8张路,梁永杰,任涛,朱辉,徐志龙,戴亚蕾.CD4^+CD25^(high) Tr细胞在非小细胞肺癌中的表达及意义[J].实用医学杂志,2009,25(13):2060-2062. 被引量：7

共引文献56

同被引文献18

  • 1Li S, Li L, Zhu Y, et al. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5 125 Chinese cohorts[J].Br J Cancer.2014, 110(11):2812-2820.
  • 2Cardarella S, Ogino A, Nishino M, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer[J].Clin Cancer Res.2013, 19(16):4532-4540.
  • 3Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small cell lung cancer harboring BRAF mutations[J].J Clin Oncol.2011, 29(26):3574-3579.
  • 4Chen D, Zhang LQ, Huang IF, et al. BRAF mutations in patients with non-small cell lung cancer, a systematic review and metaanalysis[J]. PLoS One, 2014, 9(6): e101354.
  • 5Brustugun OT, Khattak AM, Tromborg AK, et al. BRAFmutations in non-small cell lung cancer[J].Lung Cancer.2014, 84(1):36-38.
  • 6Alrifai D, Popat S, Ahmed M, et al. A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations[J].Lung Cancer.2013, 80(3):339-340.
  • 7Ohashi K, Sequist LV, Arcila ME, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1[J]. Proc Natl Acad Sci USA, 2012, 109(31): E2127-2133.
  • 8Robinson S, O′Shaughnessy J, CL C, et al. BRAF V600Emutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib[J].Lung Cancer.2014, 85(2):326-330.
  • 9Gautschi O, Milia J, Cabarrou B, et al. Targeted therapy for patients with BRAFmutant lung cancer: results from the european EURAF cohort[J].J Thorac Oncol.2015, 10(10):1451-1457.
  • 10Gibney G, Zager J. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies[J].Expert Opin Drug Metab Toxicol.2013, 9(7):893-899.

引证文献1

二级引证文献1

国际肿瘤学杂志
2015年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部